T2DM can also be treated by other antidiabetic drugs such as dipeptidyl peptidase-4 (DPP-IV) inhibitors, which extend the half-life of the native incretins, such as the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP). This evidence concerns the gene GIP and type 2 diabetes mellitus.